R3 Life reviews early evidence for NK cell therapy in brain disease

R3 Life says early human and preclinical studies are starting to test natural killer cells as a treatment path for Alzheimer’s and Parkinson’s disease. The evidence is still preliminary, and the article stresses that any therapeutic benefit remains unproven.

Why it matters: - Natural killer, or NK, cells are moving from basic immunology into early neurodegenerative disease research. - The work could reshape how scientists think about Alzheimer’s and Parkinson’s by linking brain aging to immune dysfunction, not just neuron loss. - The current evidence is promising but not enough to support NK cell therapy as a proven treatment.

What happened: - R3 Life reviewed an early Phase I Alzheimer’s study published in February 2025 and preclinical Parkinson’s findings. - The Alzheimer’s trial tested SNK01, an autologous, non-genetically modified expanded NK cell product from NKGen Biotech, now called troculeucel. - Researchers enrolled 11 people with Alzheimer’s disease, and 10 were evaluable for analysis. - Participants received intravenous NK cell infusions every three weeks for four treatments. - The study’s main goal was safety, with cognitive scores and cerebrospinal fluid biomarkers also tracked.

The details: - No adverse events were attributed to the NK cell product itself. - Procedure-related events, including injection-site pain, occurred during the infusion trial. - About 90% of evaluable participants showed stable or improved cognitive scores at the primary time point. - Two neuroinflammation-related biomarkers, pTau181 and GFAP, showed dose-dependent reductions. - The Alzheimer’s study showed that expanded NK cells can be administered to people with Alzheimer’s disease and studied directly in humans. - The trial did not show that NK cell therapy can slow, stop or reverse Alzheimer’s disease. - The study was small and early-phase, and it was designed mainly to assess safety and look for preliminary biological signals. - Larger, longer, randomized controlled trials are still needed. - A 2020 study in the Proceedings of the National Academy of Sciences found that NK cells can internalize and degrade alpha-synuclein aggregates. - In that mouse-model work, depletion of NK cells worsened alpha-synuclein pathology and neuroinflammation. - Human clinical data for NK cell therapy in Parkinson’s disease remain limited. - Evidence for direct NK-cell clearing of alpha-synuclein is stronger than evidence for a similar effect on amyloid-beta. - Current data suggest NK cells may help amyloid-beta clearance indirectly by restoring impaired microglial function. - A 2024 review in the Journal of Neuroinflammation concluded that CD56bright NK cells may be either beneficial or detrimental depending on the disease, subset and disease stage. - Roughly 90% of circulating NK cells are the CD56dim subset, which is strongly cytotoxic. - The smaller CD56bright subset is more immunoregulatory and is a potent cytokine producer.

Between the lines: - The science is shifting from asking whether NK cells matter in neurodegenerative disease to asking which NK-cell subtypes, doses and delivery methods might matter most. - The article argues that inflammation is not automatically harmful; the problem is persistent or poorly regulated inflammatory signaling. - R3 Life frames NK cell therapy as part of a broader regenerative-medicine push to influence the body’s own biological systems rather than simply replace damaged tissue. - The biggest gap is still clinical proof that NK-cell interventions change long-term neurological outcomes, not just biomarkers.

What's next: - Researchers still need to determine which NK-cell subsets are most useful, what dose and schedule work best, and how long infused cells remain functional. - Future studies must show whether NK cells can reach and influence the central nervous system in a meaningful way. - Scientists also need to identify which patients are most likely to benefit and whether treatment can alter disease progression. - Any move toward mainstream use will depend on larger randomized controlled trials. - R3 Life says NK cell therapy remains investigational and is not an approved treatment for Alzheimer’s or Parkinson’s disease.

The bottom line: - NK cells are an intriguing early target in brain-health research, but the human evidence is still too limited to call them a therapy. - The first clinical data show feasibility and safety signals, not proof of benefit.